The involvement of the vasopressin system in stress-related disorders
Abstract
The neuropeptide arginine vasopressin (AVP) is released within distinct brain areas upon appropriate stimulation, including stressful challenges. Following its predominantly dendritic release, AVP triggers a variety of receptor-mediated effects related to behavioral and neuroendocrine regulation. Antagonist treatment together with other sophisticated loss-of-function and gain-of-function approaches provide evidence for a multiple involvement of V1a and V1b receptor subtypes in stress-related behavior and disorders, including anxiety disorders, comorbid depression and their neuroendocrine concomitants. Conversely, in the high versus low anxiety (HAB/LAB) rat model, the phenotype of extreme trait anxiety is associated with a polymorphism-driven overexpression of AVP in the hypothalamic paraventricular nucleus. This overexpression of AVP might be considered a final common pathway of anxiety-related behavior. The capability of both responding to stressful stimuli and mediating genetic polymorphisms makes the central release of AVP a key process for converging (i.e., environmentally and genetically driven) behavioral regulation. Polymorphisms in the promoter structures of the AVP gene and AVP receptor genes, underlying differences in gene expression, thus contribute to individual variation in behavior as well as to psychopathology, making genes of the brain AVP system and their products a promising target for therapeutic interventions.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vasopressin's central actions are mediated by binding to V1A and V1B receptors distributed in many anxiety- and fear-related brain areas including the lateral septum, cortex and hippocampus, with V1A receptors being predominant.
“Its central actions are mediated by binding to the two G-protein coupled V 1A and V 1B receptors which are distributed in many anxiety-and fear-related brain areas including in the lateral septum, cortex and hippocampus, with V 1A receptors being the predominant receptor (Landgraf, 2006).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Landgraf, 2006
Cited by
Sorted by citations
Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954 · see citing works
Self-citationThe prefrontal cortex as a key target of the maladaptive response to stress
Cerqueira, J. J., Mailliet, F., Almeida, O. F. X., Jay, T. M., & Sousa, N. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4372-06.2007 · Cited by 599 · see citing works
“…AVP are peptides released as part of the stress response, that have receptors in several regions of the brain, including the hippocampus and the PFC (Szot et al., 1994; Herman et al., 2003); importantly, their release influences brain function and structure (Bayatti and Behl, 2005; Landgraf, 2006).”
BackgroundVasopressin: Behavioral roles of an “original” neuropeptide
Caldwell, H. K., Lee, H.-J., Macbeth, A. H., & Young, W. S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.007 · Cited by 504 · see citing works
“HAB rats display greater depressive- and anxiety-like behaviors that are accompanied by enhanced stress-induced secretion of ACTH and corticosterone than LAB rats (Landgraf et al., 1999; Landgraf, 2006).”
BackgroundStress Hormone Regulation: Biological Role and Translation into Therapy
Holsboer, F., & Ising, M. (2010) · Annual Review of Psychology · doi:10.1146/annurev.psych.093008.100321 · Cited by 473 · see citing works
“Pretreatment by dexamethasone is indeed pertinent because opposite to cortisol, low dexamethasone dosages fail to cross the blood-brain barrier and result (on a functional level) in CNS hypocortisolism, which stimulates AVP (von Bardeleben & Holsboer 1989).”
BackgroundInfluentialSex differences in oxytocin and vasopressin: Implications for autism spectrum disorders?
CARTER, C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.08.025 · Cited by 432 · see citing works
“VP has been implicated in anxiety and in the stress-related upregulation of the HPA axis [112].”
BackgroundLukas, M., Toth, I., Reber, S. O., Slattery, D. A., Veenema, A. H., & Neumann, I. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.95 · Cited by 403 · see citing works
“…because vasopressin is a key modulator of various aspects of social behavior in male rodents such as social memory (Engelmann et al, 1994), inter-male aggression (Veenema et al, 2010), and pair bonding (Wang et al, 1998), but exerts rather anxiogenic effects (for review, see Landgraf, 2006).”
BackgroundHolsboer, F., & Ising, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.032 · Cited by 380 · see citing works
“When hypersecreted over extended periods of time these initially beneficial effects reverse into increased liability for anxiety- and depression-like behavior (Landgraf, 2006).”
BackgroundResultAnisman, H., Merali, Z., & Hayley, S. P. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.004 · Cited by 334 · see citing works
“Given the effect of AVP on HPA functioning, the view was entertained that together with other peptides, AVP might contribute to anxiety and depression, and in modulation of the stress response (Landgraf, 2006).”
MANNING, M., STOEV, S., CHINI, B., DURROUX, T., MOUILLAC, B., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00437-8 · Cited by 296 · see citing works
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236 · see citing works
Aggression and anxiety: social context and neurobiological links
Neumann, I. D. (2010) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2010.00012 · Cited by 238 · see citing works
“There is also substantial evidence that AVP is an important anxiogenic factor (for reviews see Ring, 2005; Landgraf, 2006; Landgraf et al., 2007).”
BackgroundKagerbauer, S. M., Martin, J., Schuster, T., Blobner, M., Kochs, E. F., & Landgraf, R. (2013) · Journal of Neuroendocrinology · doi:10.1111/jne.12038 · Cited by 212 · see citing works
Self-citation2-Azetidinone – A new profile of various pharmacological activities
Mehta, P. D., Sengar, N. P. S., & Pathak, A. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.035 · Cited by 212 · see citing works
Landgraf, R., Kessler, M. S., Bunck, M., Murgatroyd, C., Spengler, D., Zimbelmann, M., Nußbaumer, M., Czibere, L., Turck, C. W., Singewald, N., et al. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.07.003 · Cited by 199 · see citing works
Self-citationMillan, M. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 197 · see citing works
Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Griebel, G., & Holsboer, F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3702 · Cited by 194 · see citing works
Egashira, N., Tanoue, A., Matsuda, T., Koushi, E., Harada, S., Takano, Y., Tsujimoto, G., 三島, 健., Iwasaki, K., & Fujiwara, M. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.12.009 · Cited by 193 · see citing works
Sex differences in vasopressin and oxytocin innervation of the brain
DEVRIES, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00402-0 · Cited by 169 · see citing works
“A more complete understanding of the development and function of sex differences in AVP and OXT innervation may also provide novel clues as to the origin of behavioural disorders such as depression, autism and schizophrenia (De Vries, 2004; Ring, 2005; Landgraf, 2006; Carter, 2007).”
BackgroundVeenema, A. H. (2011) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.002 · Cited by 157 · see citing works
“Because PVN–VP has been shown to modulate anxiety-related behaviors (Landgraf, 2006), it has been suggested that maternal separationinduced alterations in VP might have primarily influenced anxiety systems, which, in turn, could have resulted in species-specific regulation of aggressive behavior…”
BackgroundThe vasopressin system — From antidiuresis to psychopathology
Frank, E., & Landgraf, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.063 · Cited by 159 · see citing works
“Additionally, both neuropeptides are fundamental for the formation and/or expression of social learning and memory enabling the discrimination of familiar individuals and are involved in pair bond formation as well as in emotionality (Bielsky and Young, 2004; Hammock and Young, 2006; Landgraf, 2006; Storm and Tecott,…”
BackgroundInfluentialSelf-citationInnovative Approaches for the Treatment of Depression: Targeting the HPA Axis
THOMSON, F. J., & Craighead, M. W. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9518-3 · Cited by 155 · see citing works
“The evidence linking V1a receptor activation to these behavioural processes will not be covered in detail here having been extensively reviewed elsewhere [97].”
BackgroundBosch, O. J., Müsch, W., Bredewold, R., Slattery, D. A., & Neumann, I. D. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.12.012 · Cited by 155 · see citing works
“Prenatal stress effects on maternal behaviour an physiology in female offspring 273 psychpathologies including depression (Nemeroff, 1996; Purba et al., 1996; Arborelius et al., 1999; Keck et al., 2002; Bakshi and Kalin, 2002; Holmes et al., 2003; Landgraf and Neumann, 2004; Landgraf, 2006).”
BackgroundEpigenetic programming of the HPA axis: Early life decides
Murgatroyd, C., & Spengler, D. (2011) · Stress · doi:10.3109/10253890.2011.602146 · Cited by 138 · see citing works
“AVP critically modulates mood behaviours (Landgraf 2006; Goekoop et al. 2010), in addition to playing an important role in the postnatal development and functional maturation of the pituitary–adrenal axis; in particular, AVP potentiates the actions of CRH under circumstances demanding sustained…”
BackgroundLukas, M., Bredewold, R., Landgraf, R., Neumann, I. D., & Veenema, A. H. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.11.007 · Cited by 122 · see citing works
“In addition to its critical role in social recognition, AVP has been shown to regulate other social as well as emotional behaviors (Goodson and Bass, 2001; Engelmann et al., 2004; Landgraf, 2006; Bosch and Neumann, 2008; Veenema and Neumann, 2008; Heinrichs et al., 2009).”
Self-citationThe chemistry and biological potential of azetidin-2-ones
Arya, N., Jagdale, A. Y., Patil, T. A., Yeramwar, S. S., Holikatti, S. S., Dwivedi, J., Shishoo, C. J., & Jain, K. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.002 · Cited by 112 · see citing works
Distribution of the glucocorticoid receptor in the human amygdala; changes in mood disorder patients
Wang, Q., Verweij, E. W. E., Krugers, H. J., Joëls, M., Swaab, D. F., & Lucassen, P. J. (2013) · Brain Structure and Function · doi:10.1007/s00429-013-0589-4 · Cited by 107 · see citing works
Gruber, C. W., Muttenthaler, M., & Freissmuth, M. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793292474 · Cited by 107 · see citing works
Barrett, C. E., Keebaugh, A. C., Ahern, T. H., Bass, C. E., Terwilliger, E. F., & Young, L. J. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.01.005 · Cited by 100 · see citing works
“Conventional knockout mouse approaches often involve developmental compensation (Landgraf, 2006).”
The Neuroendocrinology of Mood Disorders
Rubín, R. T., & Carroll, B. J. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00092-9 · Cited by 103 · see citing works
Desbonnet, L., Garrett, L., Daly, E., McDermott, K. W. G., & Dinan, T. G. (2008) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2008.02.004 · Cited by 97 · see citing works
“Due to the well-established role played by AVP in social, depressive and anxious behaviours (Landgraf, 2006), alterations in this peptide system in early development are likely to have long-term consequences for the regulation of these behavioural responses to stressful and emotional situations in later life.”
Opposite effects of oxytocin and vasopressin on the emotional expression of the fear response
VIVIANI, D., & STOOP, R. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00418-4 · Cited by 96 · see citing works
Pan, Y., Liu, Y., Young, K. A., Zhang, Z., & Wang, Z. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.02.064 · Cited by 92 · see citing works
“PVN AVP has been implicated in anxiety-related behavior [29,48] by having direct actions [11,30] or through synergistic interactions with CRF [1].”
Litvin, Y., Murakami, G., & Pfaff, D. W. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.03.007 · Cited by 90 · see citing works
“Furthermore, we chose to focus onmales due to findings showing that AVP expression is greater in males than in females [61] with its synthesis being androgen-dependent in the MeA and BNST [62]; 2) AVP is implicated in various human social disorders involving aggression, stress and anxiety [19,63].”
Dempster, E. L. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1189 · Cited by 88 · see citing works
“The vasopressin V1b (AVPR1b) receptor is important in regulating pituitary corticotrophs’ responsiveness to vasopressin(14); on binding to the AVPR1b receptor, AVP activates phosphatidylinositol hydrolysis, which mobilizes intracellular Ca(2) .(12) A positive correlation exists between changes in pituitary AVPR1b rece…”
Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder
de Kloet, C. S., Vermetten, E. H. G. J. M., Geuze, E., Wiegant, V. M., & Westenberg, H. G. M. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.11.009 · Cited by 84 · see citing works
Involvement of vasopressin in affective disorders
Surget, A., & Belzung, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.065 · Cited by 81 · see citing works
Griebel, G., Beeské, S., & Stahl, S. M. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07804 · Cited by 81 · see citing works
Muttenthaler, M., Andersson, Å., Vetter, I., Menon, R., Busnelli, M., Ragnarsson, L. K. N., Bergmayr, C., Arrowsmith, S., Deuis, J. R., Chiu, H. S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aan3398 · Cited by 79 · see citing works
Azetidinones as vasopressin V1a antagonists
Guillon, C. D., KOPPEL, G. A., Brownstein, M., Chaney, M. O., Ferris, C. F., Lu, S., Fabio, K. M., Miller, M. J., Heindel, N. D., Hunden, D. C., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.12.031 · Cited by 74 · see citing works
A Hypomorphic Vasopressin Allele Prevents Anxiety-Related Behavior
Bunck, M., Czibere, L., Horvath, C., Graf, C., Frank, E., Kessler, M. S., Murgatroyd, C., Müller‐Myhsok, B., Gonik, M., Weber, P., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005129 · Cited by 73 · see citing works
Self-citationInteraction of Stress, Corticotropin-Releasing Factor, Arginine Vasopressin and Behaviour
Beurel, E., & Nemeroff, C. B. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_306 · Cited by 64 · see citing works
“These approaches include central or peripheral administration of V1 receptor antagonists, siRNA, knockout mice, and adenoviral overexpression of V1 receptors (Landgraf 2006; Mak et al. 2012; Pitkow et al. 2001; Ring 2005; Ryckmans 2010; Simon et al. 2008).”
BackgroundUnschuld, P. G., Ising, M., Roeske, D., Erhardt, A., Specht, M., Kloiber, S. M., Uhr, M., Müller‐Myhsok, B., Holsboer, F., & Binder, E. B. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.30 · Cited by 65 · see citing works
“In preclinical and clinical studies, corticotropin-releasing hormone (CRH) and vasopressin (AVP) have been shown to be the main effectors of HPA activity, important for the mediation of anxious and depressive-like behavior (Britton et al, 1986; Holsboer, 2000; Landgraf, 2006; Nemeroff and Owens, 2002; Pepin et al, 199…”
BackgroundInfluentialAbout Stress Hormones and Resilience to Psychopathology
de Kloet, E. R. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01707.x · Cited by 59 · see citing works
“In subsequent studies, oxytocin, vasopressin and vasotocin receptors were identified in brain: the peptides appeared to be crucial in the coordination of cognitive functions and socio-reproductive patterns of behaviour (10, 11) and in stress-related disorders ( 12 ).”
BackgroundEgashira, N., 三島, 健., Iwasaki, K., Oishi, R., & Fujiwara, M. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r14fm · Cited by 56 · see citing works
Neuropeptides: Relevance in treatment of depression and anxiety disorders
Madaan, V., & Wilson, D. R. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.6.1395255 · Cited by 54 · see citing works
Miyetani Chauke, A., Malisch, J. L., Robinson, C., A, T. R. D. J., & Wendy Saltzman, A. (2011) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.04.002 · Cited by 49 · see citing works
“, 1993) may have modulated the stress response in breeding and nonbreeding males, although it is unclear whether it would play a stimulatory or inhibitory role (Landgraf, 2006).”
BackgroundWang, L., Martı́nez, V., Larauche, M. H., & Taché, Y. (2008) · Brain Research · doi:10.1016/j.brainres.2008.09.094 · Cited by 52 · see citing works
Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
Simon, N. G., Guillon, C., Fabio, K. M., Heindel, N. D., Lu, S., Miller, M., Ferris, C. F., Brownstein, M., Garippa, C., & KOPPEL, G. A. (2008) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488908784534586 · Cited by 51 · see citing works
Albiston, A. L., Fernando, R. N., Yeatman, H. R., Burns, P. L., Ng, L., Daswani, D., Diwakarla, S., Pham, V., & Chai, S. Y. (2009) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2009.07.011 · Cited by 49 · see citing works
Brain vasopressin signaling modulates aspects of maternal behavior in lactating rats
Bayerl, D. S., & Bosch, O. J. (2019) · Genes, Brain and Behavior · doi:10.1111/gbb.12517 · Cited by 46 · see citing works
Giglio, M. G. D., Muttenthaler, M., Harpsøe, K., Liutkevičiūtė, Z., Keov, P., Eder, T., Rattei, T., Arrowsmith, S., Wray, S., Marek, A., et al. (2017) · Scientific Reports · doi:10.1038/srep41002 · Cited by 44 · see citing works
Rigney, N., Whylings, J., de Vries, G. J., & Petrulis, A. (2021) · Neuroendocrinology · doi:10.1159/000509421 · Cited by 42 · see citing works
Vasopressin: A Review of Therapeutic Applications
Holt, N. F., & Haspel, K. L. (2009) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2009.09.006 · Cited by 41 · see citing works
Kessler, M. S., Murgatroyd, C., Bunck, M., Czibere, L., Frank, E., Jacob, W., Horvath, C., Muigg, P., Holsboer, F., Singewald, N., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05917.x · Cited by 40 · see citing works
“An anxiogenic role of AVP has recently been confirmed in several species, including mice, rats, voles and humans (Griebel et al., 2002; Bielsky et al., 2004; Hammock et al., 2005; Storm & Tecott, 2005; Landgraf, 2006; Thompson et al., 2006).”
BackgroundSelf-citationThe role of maternal care in shaping CNS function
Nephew, B. C., & Murgatroyd, C. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.013 · Cited by 39 · see citing works
“For example, although V1 receptors are a target for the treatment of anxiety disorders (Griebel et al., 2005; Landgraf, 2006; Simon et al., 2008; Surget and Belzung, 2008), AVP is an important mediator of typical maternal care (Bosch and Neumann, 2008; Nephew and Bridges, 2008a; Nephew and Bridges, 2008b), and icv AVP…”
Wang, J., Tai, F., Yan, X., & Yu, P. (2012) · Journal of Comparative Physiology A · doi:10.1007/s00359-012-0748-8 · Cited by 39 · see citing works
Affective Neuronal Selection: The Nature of the Primordial Emotion Systems
Toronchuk, J. A., & Ellis, G. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00589 · Cited by 38 · see citing works
de Vries, G. J., Jardon, M., Reza, M., Rosen, G. J., Immerman, E., & Forger, N. G. (2008) · Endocrinology · doi:10.1210/en.2008-0448 · Cited by 36 · see citing works
The arginine vasopressin V 1b receptor gene and prosociality: Mediation role of emotional empathy
Wu, N., Shang, S., & Su, Y. (2015) · PsyCh Journal · doi:10.1002/pchj.102 · Cited by 36 · see citing works
A vasopressin/oxytocin-related conopeptide with γ-carboxyglutamate at position 8
Möller, C., & Marí, F. (2007) · Biochemical Journal · doi:10.1042/bj20061480 · Cited by 34 · see citing works
Savas, S., Hyde, A. J., Stuckless, S. N., Parfrey, P. S., Younghusband, H. B., & Green, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038953 · Cited by 33 · see citing works
“Functional and epidemiological studies have shown that this gene and its ligand vasopressin are also linked to anxiety and depression in humans and in model species [15,16].”
BackgroundBradesi, S., Martı́nez, V., Lao, L., Larsson, H., & Mayer, E. A. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90557.2008 · Cited by 33 · see citing works
“Recent experimental and clinical observations suggest that vasopressin (AVP), the comediator with CRF of the neuroendocrine and behavioral response to stress (11, 17), may also have therapeutic potential for the treatment of stress-related alterations, including anxiety and depression (18, 23, 48).”
BackgroundPharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist
Fabio, K. M., Guillon, C. D., Lu, S.-F., Heindel, N. D., Brownstein, M. J., Lacey, C. J., Garippa, C., & Simon, N. G. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23495 · Cited by 34 · see citing works
Stojicic, S., Milutinović‐Smiljanić, S., Šarenac, O., Milosavljević, S., Paton, J. F. R., Murphy, D., & Japundžić‐Žigon, N. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.013 · Cited by 32 · see citing works
“Polymorphism in the promoter structure of the VP gene and VP receptor genes has been associated with genetic susceptibility to stress and psychopathology (Landgraf, 2006), and central vasopressin contributes to cardiovascular regulation (Berecek and Swords, 1990; Okada et al., 2002).”
BackgroundGIP-Dependent Expression of Hypothalamic Genes
Ambati, S., DUAN, J., Hartzell, D. L., Choi, Y., Della‐Fera, M. A., & Baile, C. A. (2011) · Physiological Research · doi:10.33549/physiolres.932151 · Cited by 31 · see citing works
“AVP is suggested to trigger a variety of effects relating to regulation of water, glucose and electrolytes and neuroendocrine functions and may also play a role in energy balance regulation (Bray 2000, Landgraf 2006).”
BackgroundGasparyan, A., Navarro, D., Navarrete, F., & Manzanares, J. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109211 · Cited by 32 · see citing works
Further genetic evidence implicates the vasopressin system in childhood‐onset mood disorders
Dempster, E. L., Burcescu, I., Wigg, K. G., Kiss, E., Baji, I., Gádoros, J., Tamás, Z., Kapornai, K., Daróczy, G., Kennedy, J. L., et al. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06930.x · Cited by 28 · see citing works
“There is considerable support from both animal and human studies for a role for the AVP system in the aetiology of depressive symptoms (Alescio-Lautier et al., 2000; Zhou et al., 2001; Landgraf, 2006; Veenema et al., 2006).”
BackgroundResultInfluentialPeña, A., Murat, B., Trueba, M., Ventura, M. A., Wo, N. C., Szeto, H. H., Cheng, L., Stoev, S. B., Guillon, G., & Manning, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060928n · Cited by 27 · see citing works
Cudnoch‐Jędrzejewska, A., Dobruch, J. T., Puchalska, L., & Szczepanska‐Sadowska, E. K. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.01.010 · Cited by 26 · see citing works
Ramos, L., Hicks, C., Caminer, A., Couto, K., Narlawar, R., Kassiou, M., & McGregor, I. S. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.10.002 · Cited by 25 · see citing works
Selvam, R., Jurkevich, A., Kang, S. W., Mikhailova, M. V., Cornett, L. E., & Kuenzel, W. J. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02370.x · Cited by 25 · see citing works
Bschor, T., Ritter, D., Winkelmann, P., Erbe, S., Uhr, M., Ising, M., & Lewitzka, U. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027613 · Cited by 23 · see citing works
“Several other findings support central AVP overexpression in these animals [66], which is caused by a genetic variation in the promoter region of the AVP gene [67].”
BackgroundFabio, K. M., Guillon, C., Lacey, C. J., Lu, S., Heindel, N. D., Ferris, C. F., Placzek, M. S., Jones, G. B., Brownstein, M., & Simon, N. G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.013 · Cited by 24 · see citing works
Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography
Schönberger, M., Leggett, C. S., Kim, S. W., & Hooker, J. M. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.108 · Cited by 24 · see citing works
From vasotocin to stress and cognition
de Kloet, E. R. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.017 · Cited by 22 · see citing works
Tamegart, L., Abbaoui, A., Khiat, A. E., Bouyatas, M. M., & Gamrani, H. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126722 · Cited by 21 · see citing works
Balázsfi, D., Pintér, O., Klausz, B., Kovács, K., Fodor, A., Török, B., Engelmann, M., & Zelena, D. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.09.011 · Cited by 21 · see citing works
“The literature is rich in articles describing the role of AVP in anxiety and depression (e.g. (Landgraf and Wigger, 2002, Scott and Dinan, 2002, Griebel et al., 2003, Keck, 2006, Landgraf, 2006, Frank and Landgraf, 2008, Simon et al., 2008, Surget and Belzung, 2008, Ryckmans, 2010).”
BackgroundVasopressinergic control of stress-related behavior: studies in Brattleboro rats
Csikota, P., Fodor, A., Balázsfi, D., Pintér, O., Mizukami, H., Weger, S., Heilbronn, R., Engelmann, M., & Zelena, D. (2016) · Stress · doi:10.1080/10253890.2016.1183117 · Cited by 21 · see citing works
“However, it is important to be aware of the limited effect of AVP circulating in the blood directly on brain functions (Landgraf, 2006).”
BackgroundProtective Role and Functional Engineering of Neuropeptides in Depression and Anxiety: An Overview
Okdeh, N., Mahfouz, G., Harb, J., Sabatier, J., Roufayel, R., Gazo-Hanna, E., Kovacic, H., & Fajloun, Z. (2023) · Bioengineering · doi:10.3390/bioengineering10020258 · Cited by 19 · see citing works
Agorastos, A., Sommer, A., Heinig, A., Wiedemann, K., & Demiralay, C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00453 · Cited by 17 · see citing works
“Polymorphisms in the promoter structures of the AVP gene and V1b receptor genes, could thus contribute to individual variation in stress resilience but also phenotypic expression of stress-related disorders and represent a promising target for pharmacotherapeutic interventions (75).”
BackgroundCombination therapy with neuropeptides for the treatment of anxiety disorder
Gupta, P. R., & Prabhavalkar, K. S. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102127 · Cited by 17 · see citing works
Linfoot, I., Gray, M. E., Bingham, B., Williamson, M., Pinel, J. P. J., & Viau, V. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.06.008 · Cited by 17 · see citing works
“In humans and rodents, CRH and AVP may contribute to extreme trait anxiety and the comorbid expression of depression-like symptoms (Keck, 2006; Landgraf, 2006), whereas OT appears to possess anxiolytic properties (de Wied et al.”
BackgroundIncreased plasma norepinephrine concentration in psychotic depression
Goekoop, J. G., de Winter, R. F. P., Wolterbeek, R., Van Kempen, G. M. J., & Wiegant, V. M. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312436574 · Cited by 16 · see citing works
“The potential role of increased release of NE next to the increased NE–AVP correlation in PSDEP may be seen in the context of the vasopressinergic mechanisms in animal models of depression [Aguilera et al. 2008; Landgraf, 2006] and noradrenergic mechanisms involved in the hypothalamus–pituitary–adrenal (HPA) axis.”
BackgroundYang, J., Pan, Y.-J., Yin, Z., Hai, G.-F., Lu, L., Zhao, Y. Y., Wang, D., Wang, H., & Wang, G. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.03.003 · Cited by 16 · see citing works
“There is also substantial evidence that AVP is an important anxiogenic factor (Landgraf, 2006; Landgraf et al., 2007; Ring, 2005).”
BackgroundJg, G., de Winter, R., Wolterbeek, R., & Wiegant, V. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372549 · Cited by 16 · see citing works
“A more complex variant of stress-induced vasopressinergic co-activation of the HPA axis, which comprises parvocellular and magnocellular AVP synthesis and release, has been found in the genetically inbred high-anxiety behaviour (HAB) rat model (Landgraf, 2006).”
BackgroundHippocampus and Hypothalamus RNA-sequencing of WFS1-deficient Mice
Ivask, M., Pajusalu, S., Reimann, E., & Kõks, S. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.039 · Cited by 15 · see citing works
Tsolakidou, A. F., Czibere, L., Pütz, B., Trümbach, D., Panhuysen, M., Deussing, J. M., Wurst, W., Sillaber, I., Landgraf, R., Holsboer, F., et al. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-546 · Cited by 16 · see citing works
Self-citationHypothalamic stress systems in mood disorders
(2021) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-819973-2.00003-4 · Cited by 15 · see citing works
Molecular Biological Aspects of Depressive Disorders: A Modern View
Ushakova, V. M., Morozova, A. Y., Reznik, A. M., Kostyuk, G. P., & Chekhonin, V. P. (2020) · Molecular Biology · doi:10.1134/s0026893320050118 · Cited by 15 · see citing works
The Potential Role of Glucocorticoids and the HPA Axis in Alcohol Dependence
Stephens, M. A. C., McCaul, M. E., & Wand, G. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405941-2.00021-3 · Cited by 16 · see citing works
Oxytocin/vasopressin-like neuropeptide signaling in insects
Muratspahić, E., Monjon, E., Duerrauer, L., Rogers, S. M., Cullen, D. A., Broeck, J. V., & Gruber, C. W. (2020) · Vitamins and hormones · doi:10.1016/bs.vh.2019.08.011 · Cited by 14 · see citing works
“…Douglas, & Neumann, 2005; Wersinger, Ginns, O’Carroll, Lolait, & Young, 2002), attachment (Insel & Young, 2001), anxiety-related behavior (Landgraf, 2006), fear conditioning (Eckstein et al., 2015), labor (Gruber & O’Brien, 2011), social recognition (Kirsch et al., 2005), and memory and…”
From the Stalk to Down Under about Brain Glucocorticoid Receptors, Stress and Development
de Kloet, E. R., Han, F., & Meijer, O. C. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9520-9 · Cited by 14 · see citing works
“Such imbalance may be due to inadequate or excessive corticosteroid action or related variants in MR and GR, that are of genetic origin or induced by environmental factors going back as far as perinatal experiences [15, 33, 34].”
BackgroundCheignon, C., Cordeau, E., Prache, N., Cantel, S., Martínez, J., Subra, G., Arnaudguilhem, C., Bouyssière, B., & Enjalbal, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01320 · Cited by 14 · see citing works
Cudnoch‐Jędrzejewska, A., Szczepanska‐Sadowska, E. K., Dobruch, J. T., Puchalska, L., Ufnal, M., Kowalewski, S., & Wsół, A. (2008) · Stress · doi:10.1080/10253890701794445 · Cited by 11 · see citing works
“…such vital functions as thirst and sodium appetite, and in the release of the hypothalamic and pituitary hormones (Armando et al. 2002; Carrasco and Van de Kar 2003; Fitzsimons 1979; Kovacs and Sawchenko 1996; Landgraf 2006; Mayorov et al. 2004; Saad and Camargo 2003; Saavedra et al. 2005, 2006).”
BackgroundHiguchi, Y., & Arakawa, H. (2022) · Hormones and Behavior · doi:10.1016/j.yhbeh.2022.105128 · Cited by 9 · see citing works
Chapter 4.1 Peptide receptor ligands to treat anxiety disorders
Steckler, T. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)00010-0 · Cited by 10 · see citing works
Das, S., Komnenov, D., Newhouse, L., Rishi, A. K., & Rossi, N. F. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113867 · Cited by 9 · see citing works
Goekoop, J. G., de Winter, R. F. P., Wolterbeek, R., Kempen, G. M. J. V., & Wiegant, V. M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109349839 · Cited by 9 · see citing works
“The High Anxiety-related Behaviour (HAB) rat, which has been developed by inbreeding for the trait of avoiding an anxiety-provoking condition, has been found to be characterized by increased synthesis and release of AVP, and by high anxiety combined with high immobility after stress (Landgraf, 2006).”
BackgroundSchmidt, M. V., & Müller, M. B. (2006) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2006.11.002 · Cited by 10 · see citing works
Landgraf, R., & Holsboer, F. (2005) · Drug Development Research · doi:10.1002/ddr.20022 · Cited by 9 · see citing works
Self-citation
- Authors
- Landgraf, R.
- Affiliations
- Max Planck Institute of Psychiatry (DE)
- Corresponding author
- Landgraf, Rainer
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-04-01
- Volume
- 5
- Issue
- 2
- Pages
- 167-179
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- OpenAlex
- W2027012370
- Cited by
- 127
- References
- 0
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 1 · 2014: 7 · 2013: 6 · 2012: 8
- FWCI
- 22.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS & Neurological Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- vasopressin, vasopressin receptor, V1a receptor, V1b receptor, stress-related disorders, anxiety disorders, comorbid depression, hypothalamic paraventricular nucleus, trait anxiety, gene expression, neuroendocrine regulation, stress response, individual variation in behavior, therapeutic target
- MeSH terms
- Animals, Anxiety Disorders, Arginine Vasopressin, Gene Expression Regulation, Humans, Hypothalamo-Hypophyseal System, Paraventricular Hypothalamic Nucleus, Stress, Physiological, Receptors, Vasopressin, Mood Disorders, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
